


Antitumor agent-88

Cat. No.:	HY-148595
CAS No.:	1422527-87-4
Molecular Formula:	C ₂₃ H ₃₀ N ₂ O ₇ S
Molecular Weight:	478.56
Target:	Cytochrome P450
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Antitumor agent-88 exhibits potent antimetabolic activity and arrests cell in the G2/M phase. Antitumor agent-88 disrupts the microtubule and the cytoskeleton in CYP1A1-expressing breast cancer cells. Antitumor agent-88 is also a competitive inhibitor of CYP1A1 (K _i : 1.4 μM) ^[1] .								
IC₅₀ & Target	CYP1A1 1.4 μM (K _i)								
In Vitro	<p>Antitumor agent-88 (Compound 14, 48 h) inhibits MCF-7 cell growth, with an IC₅₀ of 200 nM, and is inactive on MDA-MB-231 (IC₅₀ >8600 nM)^[1].</p> <p>Antitumor agent-88 inhibits MDA-MB-468, SK-BR cell growth with IC₅₀s of 21 nM, 3.2 nM^[1].</p> <p>Antitumor agent-88 (50 nM, 48 h) causes accumulation of the cells in the G2/M phase by 42%^[1].</p> <p>Antitumor agent-88 shows high affinity for CYP1A1 (K_i: 1.4 μM)^[1].</p> <p>Antitumor agent-88 selectively inhibits HT-1080 cell proliferation, with IC₅₀s of 30 nM for HT-1080 transfected with CYP1A1^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MCF-7 cell</td> </tr> <tr> <td>Concentration:</td> <td>50 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Arrested cell in G2/M phase.</td> </tr> </table>	Cell Line:	MCF-7 cell	Concentration:	50 nM	Incubation Time:	48 h	Result:	Arrested cell in G2/M phase.
Cell Line:	MCF-7 cell								
Concentration:	50 nM								
Incubation Time:	48 h								
Result:	Arrested cell in G2/M phase.								
In Vivo	<p>Antitumor agent-88 (Compound 14) (1 μg/egg) shows antitumoral activities in the chick embryos bearing HT-1080CYP1A1 tumors^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Chick embryos grafted with HT-1080CYP1A1 cells^[1]</td> </tr> <tr> <td>Dosage:</td> <td>1 μg/egg</td> </tr> <tr> <td>Administration:</td> <td>Applied to chick chorioallantoic membrane.</td> </tr> </table>	Animal Model:	Chick embryos grafted with HT-1080CYP1A1 cells ^[1]	Dosage:	1 μg/egg	Administration:	Applied to chick chorioallantoic membrane.		
Animal Model:	Chick embryos grafted with HT-1080CYP1A1 cells ^[1]								
Dosage:	1 μg/egg								
Administration:	Applied to chick chorioallantoic membrane.								

Result:	Reduced tumor weight by 49%.
---------	------------------------------

REFERENCES

[1]. Chavez Alvarez AC, et al. Homologation of the Alkyl Side Chain of Antimitotic Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonate Prodrugs Selectively Targeting CYP1A1-Expressing Breast Cancers Improves Their Stability in Rodent Liver Microsomes. J Med Chem. 2023 Feb 23;66(4):2477-2497.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA